ADVERTISEMENT
ADVERTISEMENT

Abcam enables faster drug and biomarker discovery with immunoassay research suite

Matched antibody pair kits provide assays with reporducible, sensitive and high-throughput detection.      

Abcam

Abcam plc, a global leader in the supply of life science research tools, today announced the launch of a suite of immunoassay products based on its recombinant, monoclonal antibody pairs, as part of its commitment to deliver quality reagents to life science researchers at scale.

Matched antibody pairs are central to enzyme-linked immunoabsorbant assays (ELISAs), which are widely used to study secreted biomarkers, and are fundamental to research in areas such as immunology and cancer. Abcam optimises its antibody pairs to avert the reproducibility and scalability challenges previously faced by researchers, which can cause variability in results. Abcam’s matched antibody pairs use recombinant monoclonal antibody technology, such as the patented RabMAb® technology, to provide improved consistency over polyclonal antibodies. The pairs are screened for sensitive performance and rigorously tested in a variety of complex sample types including plasma, serum and cell lysates.

These optimised pairs are already part of...

Alejandra Solache, Head of Production, Development and Manufacturing at Abcam, said: “By providing researchers with highly optimised matched antibody pairs in a stand-alone format, we’re enabling scale up to higher-throughput assay platforms and faster drug discovery. Our recombinant monoclonal antibody pairs are inherently reproducible, providing reliable results the first time as well as supporting long-term use.”

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT